Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a preliminary median progression-free survival of 15.2 months. The drug demonstrated robust central nervous system activity with an 86% objective response rate in brain metastases and no patients developing de novo brain metastases during the study.
Key figures
- Drug Name
- silevertinib
- Phase Of Trial
- Phase 2
- Dcr pct
- 91
- Dose mg
- 200
- Cns orr pct
- 86
- M PFS months
- 15.2
- Overall orr pct
- 60
- Trae grade3 pct
- 28
- Patients enrolled
- 43
- Median follow up months
- 11.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.